Biodexa Pharmaceticals Stock Performance
| BDRX Stock | 4.93 0.13 2.71% |
The firm shows a Beta (market volatility) of 3.14, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biodexa Pharmaceticals will likely underperform. At this point, Biodexa Pharmaceticals has a negative expected return of -0.98%. Please make sure to confirm Biodexa Pharmaceticals' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Biodexa Pharmaceticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biodexa Pharmaceticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.71 | Five Day Return 15.19 | Year To Date Return (92.67) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:25 | Dividend Date 2020-03-03 | Last Split Date 2024-10-04 |
1 | Biodexa Pharmaceuticals Shares Scheduled to Reverse Split on Friday, October 4th | 10/03/2024 |
2 | Biodexa Pharmaceuticals Stock Is Soaring After The Close Whats Driving Shares Higher | 10/15/2024 |
3 | Lost Money on Biodexa Pharmaceuticals Plc Contact Levi Korsinsky Regarding an Ongoing Investigation | 10/16/2024 |
4 | Biodexas MX-110 Continues to Show Promise in Recurrent Glioblastoma , the Deadliest Brain Cancer | 10/17/2024 |
5 | Levi Korsinsky Announces an Investigation on Behalf of Biodexa Pharmaceuticals Plc Shareholders Who May Have Been Affected by Fraud | 10/21/2024 |
6 | Biodexa Pharmaceuticals Plc INVESTIGATION Levi Korsinsky Investigates Potential Securities Fraud by Biodexa Pharmaceuticals Plc | 10/23/2024 |
7 | ATTENTION Biodexa Pharmaceuticals Plc Investors You May Have Been Affected by Fraud - Contact Levi Korsinsky to Discuss Your Rights | 10/29/2024 |
8 | Biodexa Pharmaceuticals PLC Regains Compliance For Continued Listing on Nasdaq | 11/12/2024 |
9 | Result of General Meeting | 11/22/2024 |
| Begin Period Cash Flow | 2.8 M | |
| Free Cash Flow | -7.1 M |
Biodexa |
Biodexa Pharmaceticals Relative Risk vs. Return Landscape
If you would invest 1,375 in Biodexa Pharmaceticals on August 30, 2024 and sell it today you would lose (882.00) from holding Biodexa Pharmaceticals or give up 64.15% of portfolio value over 90 days. Biodexa Pharmaceticals is currently does not generate positive expected returns and assumes 12.0356% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Biodexa, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biodexa Pharmaceticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biodexa Pharmaceticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biodexa Pharmaceticals, and traders can use it to determine the average amount a Biodexa Pharmaceticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0815
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BDRX |
Estimated Market Risk
| 12.04 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.98 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biodexa Pharmaceticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biodexa Pharmaceticals by adding Biodexa Pharmaceticals to a well-diversified portfolio.
Biodexa Pharmaceticals Fundamentals Growth
Biodexa Stock prices reflect investors' perceptions of the future prospects and financial health of Biodexa Pharmaceticals, and Biodexa Pharmaceticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biodexa Stock performance.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (79.31) % | ||||
| Current Valuation | (3.01 M) | ||||
| Shares Outstanding | 580.84 K | ||||
| Price To Book | 0.26 X | ||||
| Price To Sales | 34.50 X | ||||
| Revenue | 381 K | ||||
| Gross Profit | (4.41 M) | ||||
| EBITDA | (7.16 M) | ||||
| Net Income | (7.08 M) | ||||
| Total Debt | 464 K | ||||
| Book Value Per Share | 24.07 X | ||||
| Cash Flow From Operations | (6.83 M) | ||||
| Earnings Per Share | (75.43) X | ||||
| Market Capitalization | 2.86 M | ||||
| Total Asset | 10.54 M | ||||
| Retained Earnings | (144.77 M) | ||||
| Working Capital | 1.46 M | ||||
About Biodexa Pharmaceticals Performance
Evaluating Biodexa Pharmaceticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Biodexa Pharmaceticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biodexa Pharmaceticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (63.18) | (60.02) | |
| Return On Tangible Assets | (0.93) | (0.98) | |
| Return On Capital Employed | (1.61) | (1.53) | |
| Return On Assets | (0.67) | (0.71) | |
| Return On Equity | (1.51) | (1.59) |
Things to note about Biodexa Pharmaceticals performance evaluation
Checking the ongoing alerts about Biodexa Pharmaceticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biodexa Pharmaceticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biodexa Pharmaceticals generated a negative expected return over the last 90 days | |
| Biodexa Pharmaceticals has high historical volatility and very poor performance | |
| Biodexa Pharmaceticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 381 K. Net Loss for the year was (7.08 M) with loss before overhead, payroll, taxes, and interest of (4.41 M). | |
| Biodexa Pharmaceticals generates negative cash flow from operations | |
| Biodexa Pharmaceticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Result of General Meeting |
- Analyzing Biodexa Pharmaceticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biodexa Pharmaceticals' stock is overvalued or undervalued compared to its peers.
- Examining Biodexa Pharmaceticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biodexa Pharmaceticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biodexa Pharmaceticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biodexa Pharmaceticals' stock. These opinions can provide insight into Biodexa Pharmaceticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.